The Smith-Lemli-Opitz syndrome is a recessive inherited disorder characterized by neurologic developmental defects and dysmorphic features in many organs. Recently, abnormal cholesterol biosynthesis with impaired conversion of 7-dehydrocholesterol to cholesterol has been discovered in homozygotes. To reproduce the biochemical abnormality, BM 15.766, a competitive inhibitor of 7-dehydrocholesterol-A7-reductase, the enzyme that catalyzes the conversion of 7-dehydrocholesterol into cholesterol was fed by gavage to rats. After 14 d, plasma cholesterol concentrations declined from 48 mg/dl to 16 mg/dl and 7-dehydro-cholesterol levels rose from trace to 17 mg/dl. Hepatocytes surrounding the central vein developed balloon necrosis. Stimulating cholesterol synthesis with cholestyramine followed by BM 15.766 produced an additional 40% decline (P < 0.05) in plasma cholesterol and 34% increase in 7-dehydrocholesterol levels compared to the inhibitor alone. Adding 2% cholesterol to the diet during the second week of BM 15.766 treatment increased plasma cholesterol threefold and decreased 7-dehydrocholesterol concentrations 55 %. Hepatic 3-hydroxy-3-methylglutaryl co-enzyme A (HMG-CoA) reductase activity increased 73% with a 3.9-fold rise in mRNA levels but cholesterol 7a-hydroxylase activity decreased slightly though mRNA levels increased 1.4 times with BM 15.766 treatment. These results demonstrate that BM 15.766 is a potent inhibitor of 7-dehydrocholesterol-A7-reductase. The model reproduces abnormal cholesterol biosynthesis as seen in the Smith-Lemli-Opitz syndrome and is useful to test different treatment strategies. Stimulating early steps of cholesterol synthesis worsens the biochemical abnormalities while feeding cholesterol inhibits abnormal synthesis, improves the biochemical abnormalities and prevents liver damage. (J. Clin. Invest. 1995. 95:76-81.)
Introduction
The Smith-Lemli-Opitz syndrome is an autosomal recessive disorder characterized by severe mental retardation with neuro-logic dysfunction, failure to thrive, and distinctive dysmorphic features, that was first described in 1964 (1) . The most prominent clinical manifestations include microcephaly, micrognathia, wide spread eyes, cataracts, flat nares, low set posteriorly rotated ears, and syndactyl. The prevalence of homozygotes is about 1 in 20,000 births (2) with an estimated carrier frequency of 1 to 2% (3) .
Recently, we reported that homozygotes with the SmithLemli-Opitz syndrome show abnormal cholesterol biosynthesis with extremely low cholesterol levels and the accumulation of the cholesterol precursor, 7-dehydrocholesterol, and two related dehydrocholesterol isomers in plasma and tissues (4) . The biochemical abnormalities probably result from incomplete conversion of the cholesterol precursor, 7-dehydrocholesterol to cholesterol suggesting that the microsomal enzyme which catalyzes this reaction, 7-dehydrocholesterol-A&-reductase is abnormal (Fig. 1 ).
In 1986, Pill and colleagues reported that BM 15.766, a synthetic piperazine derivative, inhibited the conversion of 7- dehydrocholesterol to cholesterol in cultured rat hepatocytes (5) and in rats (6) . Other inhibitors of cholesterol synthesis such as AY-9944, trans-1,4-bis (2-dichlorobenzylaminomethyl) cyclohexane dihydrochloride (7) which also blocks 7-dehydrocholesterol-A'-reductase and triparanol, 1-[p-(2-diethylaminoethoxy) -phenyl ] -1-(p -tolyl) -2-(p -chlorophenyl) ethanol, an inhibitor of desmosterol-24-reductase (8) , when fed to pregnant animals, may produce severe congenital abnormalies in their offspring. (9) (10) (11) . Some of the congenital defects resemble those found in homozygotes with the Smith-Lemli-Opitz syndrome and suggest that defects in cholesterol synthesis are capable of producing congenital abnormalies common to the phenotype. In this paper, we describe the effects of BM 
Chemical analysis
Assays for bile acids and sterols. Bile acids were extracted from the bile (100 Al) and deconjugated and methylated as described previously ( 12) . Trimethylsilyl ether derivatives were prepared and bile acids were quantitated by capillary gas-liquid chromatograghy on a Hewlett-Packard model 5890A (Hewlett-Packard, Palo Alto, CA) equipped with a 25-m fused silica CP-Sil 5-CB capillary column (7) . Neutral sterols were extracted with hexane from 1 ml plasma or 0.5 ml bile after saponification in IN ethanolic NaOH. Trimethylsilyl ether derivatives were prepared and quantitated by capillary gas-liquid chromatography as described previously (13 After lactonization at 37°C for 30 min, the products were separated by thin-layer chromatography, and mevalonolactone quantitated by liquid scintillation counting (17) . Cholesterol 7a-hydroxylase activity was measured in hepatic microsomes by the isotope incorporation method of Shefer et al. (14) .
Isolation and quantitation of mRNA. Total RNA from samples of frozen liver was isolated by the acid guanidinium thiocyanate-phenolchloroform extraction method ( 18) . Portions of frozen liver, 0.2 g, were homogenized in 2 ml of room temperature TRI Reagent purchased from Molecular Research Center, Cincinnati, Ohio, using a Polytron Tissue Disrupter at full speed for 5-10 s. After 5 min, 0.4 ml of chloroform was added, the sample mixed vigorously and centrifuged at 12,000 g for 15 min at 4°C. The aqueous phase was removed and 1 ml of isopropanol was added. The samples were mixed and allowed to stand at room temperature for 5-10 min, then centrifuged at 12,000 g for 10 min at 4°C. The pelleted RNA was then washed in 75% ethanol. The total RNA pellet was dissolved in 100 jA of diethylpyrocarbonate treated water. Poly(A)+ RNA was isolated by oligo (dT) cellulose chromatography (19) . The relative levels of HMG-CoA reductase and cholesterol 7a-hydroxylase mRNA were quantitated by Northern blotting analysis as previously described (20) except that a Red Roller hybridization oven from Hoefer Scientific Instruments was used. /3-Actin was served as the internal standard. The cDNAs for hamster HMG-CoA reductase, pRED 227 and human ,8-actin, HHC1 89 were purchased from American Type Culture collection (Rockville, MD). The cDNA for rat liver cholesterol 7a-hydroxylase, 7a6, was a gift from Dr. J. Y. L. Chiang (Northeastern Ohio University, Rootstown, OH).
Statistical study
Data were analyzed statistically using the unpaired Student's t test.
Results
Measurements of plasma cholesterol and 7-dehydrocholesterol levels in rats treated with BM 15.766 are given in Table I . After 3 d of BM 15.766 feeding, plasma cholesterol concentrations declined 40% (P < 0.05) and 7-dehydrocholesterol levels which were barely detected in untreated controls, increased markedly. Continuing the treatment for 2 wk resulted in a 67% decline for plasma cholesterol (P < 0.0001) and a further rise (+60%) in 7-dehydrocholesterol levels. Discontinuation of the inhibitor for 2 wk allowed plasma cholesterol concentrations to Inhibition of 7-Dehydrocholesterol-A 7-Reductase in Rats 77 -ffi recover to the pretreatment level at which time 7-dehydrocholesterol disappeared from the plasma. The changes in biliary sterol and bile acid outputs during these treatment periods are listed in Table II. After 2 wk of feeding BM 15.766, biliary cholesterol secretion was reduced 53% (P < 0.0001) with a marked increase of 7-dehydrocholesterol, so that the precursor was 1.8 times more abundant than cholesterol in the bile. Discontinuing the inhibitor for 2 wk, restored biliary cholesterol outputs to normal levels and eliminated 7-dehydrocholesterol from the bile.
Total biliary bile acid outputs which represent the hepatic bile acid flux declined 18% (P < 0.05) after 2 wk of BM 15.766. After the inhibitor was stopped for 2 wk, the biliary bile acid output rebounded 68% (P < 0.0005) which was 37% greater (P < 0.05) than the bile acid output in the untreated rats (Table II) . Cholic acid was the major biliary bile acid and accounted for 77±5% of the total bile acids. The proportion rose to 88±4% after 2 wk treatment with BM 15.766 and returned to pretreatment value after discontinuation of the inhibitor.
Figs. 2 and 3 show the changes in plasma cholesterol and 7-dehydrocholesterol concentrations in rats when either 2.5% cholestyramine or 2% cholesterol was added to the diet in combination with BM 15.766. When cholestyramine was given together with BM 15.766 (Fig. 2) , plasma cholesterol levels declined an additional 40% (P < 0.05) and 7-dehydrocholesterol rose 34%, as compared with levels after BM 15.766 feeding for 3 d. In contrast, when 2% cholesterol was added to the diet during the second week of BM 15.766 feeding (Fig. 3) , plasma cholesterol concentrations increased threefold (P < 0.0001), which was 20% above the control level while 7-dehydrocholesterol levels were reduced 50% (P < 0.005) as compared with 2 wk of BM 15.766 feeding alone.
Activities for hepatic HMG-CoA reductase and cholesterol 7a-hydroxylase, the respective rate-controlling enzymes for cholesterol and bile acid synthesis are reported in Table III Figure 5 . Northern blot analysis of rat hepatic cholesterol 7a-hydroxylase mRNA levels (7a). After 2 wk treatment with BM 15.766 (+I), mRNA levels of hepatic cholesterol 7a-hydroxylase increase and remain higher after BM 15.766 has been withdrawn (IW) for 2 wk. Three cholesterol 7a-hydroxylase transcripts are noted at 4.0, 3.6 and 2.1 kb.
wk restored normal liver histology although increased mitochondria and rough endoplasmic reticulum persisted (not shown).
Discussion
These results confirm that BM 15.766 is a potent inhibitor of cholesterol biosynthesis. By blocking 7-dehydrocholesterol-A 7-reductase (Fig. 1) , BM 15.766 caused a marked reduction in plasma cholesterol levels associated with an enormous increase in the concentration of the cholesterol precursor, 7-dehydrocholesterol. Biliary cholesterol outputs also declined markedly with the excretion of 7-dehydrocholesterol enhanced so that the ratio of the precursor to cholesterol was 1.7 times greater in bile than in plasma. The elevated enrichment of 7-dehydrocholesterol relative to cholesterol in bile not only reflects the enzymatic block and inability of 7-dehydrocholesterol to be transformed to cholesterol but also suggests that 1.8 times more 7-dehydrocholesterol than cholesterol is produced since biliary sterol outputs probably mirror endogenous hepatic sterol synthesis. 2 wk after the inhibitor (BM 15.766) was discontinued, the cholesterol biosynthetic pathway had normalized: plasma cholesterol concentrations and biliary cholesterol outputs were restored and 7-dehydrocholesterol was eliminated from plasma and bile. This suggests that the inhibition of cholesterol biosynthesis by BM 15.766 is reversible and that newly formed 7- (Fig. 2) . The increased formation of the early precursor, mevalonic acid, which is the product of HMG-CoA and almost totally committed to the cholesterol biosynthetic pathway, mostly ended as 7-dehydrocholesterol in the BM 15.766 treated rats because of the inhibition of 7-dehydrocholesterol-A7-reductase. In a preliminary report, Shefer et al. (22) showed that 7-dehydrocholesterol-A7-reductase activity in the liver of rats treated with BM is not affected by inhibition of 7-dehydrocholesterol-A 7-reductase. The double bond in the side chain at C-24 can be reduced easily and all desmosterol intermediates transferred to the 7-dehydrocholesterol pathway. In addition, the deficiency of cholesterol in BM 15.766-treated animals and patients with the Smith-Lemli-Opitz syndrome strongly indicates that the desmosterol pathway is not separate from the pathway through which 7-dehydrocholesterol is used and can not produce cholesterol independently when the A 7 reductase is blocked. (Fig. 1) In summary, BM 15.766 is a powerful inhibitor of 7-dehydrocholesterol-A 7-reductase reproducing the biochemical defects of low plasma cholesterol with high 7-dehydrocholesterol levels, found in homozygotes with the Smith-Lemli-Opitz syndrome. Stimulating cholesterol synthesis with cholestyramine worsens the biochemical abnormalities while feeding cholesterol shuts down abnormal cholesterol synthesis and restores cholesterol in the plasma and tissues.
